JPRN-UMIN000000763
Completed
未知
Phase II study of rituximab in patients with severe systemic lupus erythematosus - Rituximab clinical investigation in severe systemic lupus erythematosus
ConditionsSystemic lupus erythematosus
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Systemic lupus erythematosus
- Sponsor
- Zenyaku Kogyo Co., Ltd.
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.SLE exclusion 1\)APS complication 2\.General health exclusion 1\)Pregnant women or lactating mothers 2\)History of severe allergic or anaphylactic reactions to humanized antibodies, murine antibodies or murine\-derived products 3\)Uncontrolled disease in any organ system not related to SLE 4\)Require treatments with systemic corticosteroid within one year, etc 3\.Medication exclusion 1\)Treated with any B\-cell targeted therapy 2\)Received other investigational drug within 6 months, or participating another clinical investigation 3\)Received a vaccine within 4 weeks, etc 4\.Laboratory exclusion 1\)AST, ALT\>Nu x 2\.5 2\)serum creatinine\>8\.0mg/dL 3\)neutrophil\<1500/uL 4\)Hb\<7\.0g/dL 5\)thrombocyte\<10,000/uL 6\)Positive HIV, HCV, HBs, HBc
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase II study of rituximab in refractory or relapsed patients with multiple myeloma expressing CD20Multiple myeloma expressing CD20JPRN-UMIN000000531Zenyaku Kogyo Co., Ltd.39
Recruiting
Phase 2
Phase II study of ramucirumab for the patients with advanced hepatocellular carcinoma previously treated with lenvatinibHepatocellular carcinomaJPRN-jRCT1041190083Yamashita Tatsuya33
Completed
Not Applicable
Phase II study of Rituximab in Patients with Systemic Lupus ErythematosusSystemic lupus erythematosusJPRN-UMIN000000762Zenyaku Kogyo Co., Ltd.70
Active, not recruiting
Not Applicable
Efficacy and safety of rituximab in patients with rheumatoid arthritis - FIRSTRheumatoid arthritisMedDRA version: 8.1Level: PTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-001000-37-DERoche Pharma AG300
Completed
Not Applicable
Efficacy and safety of rituximab for patients with severe rheumatic diseaseChildhood-onset severe rheumatic disease (systemic lupus erhythematosus, dermatomyositis, poly myositis, systemic sclerosis , mixed connective tissue disease, Sjogren's syndrome, anti-phospholipid syndrome)JPRN-UMIN000018376Yokohama City University Hospital Department of Pediatrics20